PETALING JAYA: Mah Sing Group Bhd’s indirectly owned unit, Mah Sing Healthcare Sdn Bhd, has received the 510(k) premarket notification clearance to market its nitrile examination gloves and tested for use with chemotherapy drugs from the United States Food and Drug Administration (FDA).
“With the updated 510(k) clearance, Mah Sing Healthcare will be able to market medical-grade examination gloves which can be used in the handling or preparation of chemotherapeutic drugs in the US.
“This will enable big medical players in the US to obtain gloves from Mah Sing Healthcare as their existing suppliers also carry the chemotherapy protection claim,” the group said in a statement yesterday.
This shall be updated on the FDA website in due course, it said.
Mah Sing said chemotherapy protection was often a critical consideration when evaluating examination gloves.
Healthcare personnel generally use gloves which carry the label: Tested for use with (name of chemotherapeutic drug(s)), it added.
This is to prevent unknowingly exposing themselves to chemotherapy drugs that may penetrate the gloves they use, it said.
The group noted that chemo-tested nitrile gloves were the preferred option for chemotherapy treatment, as nitrile is highly resistant against these chemicals.
Mah Sing Healthcare’s nitrile gloves have been tested and approved to protect against 11 chemotherapy drugs, it said.
Source: The Star
